RAB40AL Gene X-Linked Intellectual Disability (XLID) Genetic Test in UAE | 2800 AED

Executive Summary & Core Metrics

✓

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).

✓

Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).

✓

Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed Consultant Medical Genetics specialist.

✓

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Clinical Turnaround: 3–4 Weeks with comprehensive molecular report and genetic counselling summary.

Test Overview & Methodology

This test analyses the entire coding region of the RAB40AL gene using next-generation sequencing (NGS) to detect pathogenic variants causing X-linked intellectual disability (XLID). The assay delivers unmatched precision for diagnostic confirmation, carrier detection, and family planning—optimized for UAE population-specific variants and includes copy number variant (CNV) detection across all exons.

Parameter	Our Test (NGS – XLID Precision Panel)	Closest Alternative (Sanger Panel)
Precision	99.9% single-nucleotide resolution with CNV detection across entire coding region	Limited to targeted exons; may miss large rearrangements or splice-site variants
Methodology	NGS with bidirectional Sanger confirmation, ISO 9001:2015 accredited laboratory	Sanger sequencing only, lower multiplex capability, higher per-base cost
Turnaround Time	3–4 Weeks including clinical interpretation and report	5–6 Weeks due to sequential exon-by-exon analysis

Physician Insight & Safety Protocols

“As a DHA-licensed Consultant Medical Genetics specialist, I emphasize that this test provides a definitive molecular diagnosis for X-linked intellectual disability, but results must be correlated with detailed neurological and developmental assessments. Pre- and post-test genetic counselling is mandatory to interpret the implications for the patient and at-risk family members. Never interpret results in isolation—always involve a multidisciplinary team including a neurologist, geneticist, and developmental pediatrician.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory Pre-Test Considerations

A mandatory pre-test genetic counselling session with a DHA-licensed genetic counsellor is required before sample collection to discuss test limitations, potential incidental findings, and implications for family members. Informed consent must be documented in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Contact our counselling team via WhatsApp +971 54 548 8731 to schedule an appointment.

Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria

Asymptomatic minors without a confirmed family history of XLID or developmental delay, unless authorized by a DHA-certified genetic counsellor with parental consent.
Recent blood transfusion or bone marrow transplant – wait 6–8 weeks post-transfusion. Active systemic infection may affect DNA yield; reschedule until clinically resolved.

Emergency Red Flags

Acute neurological deterioration: If the patient develops seizures, loss of consciousness, or sudden developmental regression, proceed to the nearest emergency department immediately—do not wait for genetic results.
Medication caution: Do not discontinue or adjust prescribed medications based solely on genetic findings. Always consult your treating physician before any therapeutic changes.

Patient FAQ & Clinical Guidance

1. What does the RAB40AL gene test detect and who should consider it?

This test detects pathogenic variants in the RAB40AL gene responsible for X-linked intellectual disability (XLID), developmental delay, and associated behavioural abnormalities. It is indicated for males with unexplained intellectual disability of unknown aetiology, females with a family history of XLID seeking carrier status, and families with a known RAB40AL variant requiring reproductive planning. The test is also recommended when clinical features include mild to severe intellectual disability with or without seizures, autism spectrum features, or subtle dysmorphic findings.

2. How is the test performed and what sample is needed?

A small venous blood sample (EDTA tube, 3–5 mL) is collected at home by a certified phlebotomist through our VIP Mobile Phlebotomy service. Alternatively, a dried blood spot on an FTA card can be used for paediatric cases. Extracted DNA undergoes whole-exon capture and NGS sequencing with Sanger confirmation of all detected variants. No fasting is required, but a completed pre-test genetic counselling session must be documented before sample collection.

3. What is the turnaround time and total cost in the UAE?

Results are delivered within 3 to 4 weeks of sample receipt at the laboratory. The total cost is 2800 AED, inclusive of genetic counselling, NGS analysis, and a comprehensive clinical report. Most UAE insurance plans cover genetic testing for medically indicated conditions—contact our billing team via WhatsApp +971 54 548 8731 for direct insurance verification and pre-authorisation assistance.

4. What do the results mean and how will I receive them?

Results are classified as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign according to ACMG/AMP guidelines. A VUS may require further segregation analysis in family members. Your referring physician and the genetics team will discuss implications during a post-test telephonic counselling session. A secure PDF report is shared via encrypted email or DHA-approved health information exchange, and a telephonic consultation with the Consultant Medical Genetics is scheduled within 5 business days of report finalisation.

UAE Regulatory & Data Privacy Adherence

Data Protection & Legal Compliance

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – all genetic and personal data are processed under strict consent-based protocols with right to access, rectification, and erasure.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensures secure electronic health record handling and encrypted data transmission across all platforms.
Federal Decree-Law No. 4 of 2016 on Medical Liability – governs pre-test informed consent, clinical responsibility, and post-test counselling obligations for all genetic testing procedures.
DHA Regulatory Framework – this test is performed under DHA Facility License 1143, adhering to Dubai Healthcare City Authority quality standards and international accreditation requirements.

All genetic results are shared exclusively with the referring physician and patient after explicit written consent. No third-party disclosure occurs without separate authorisation.

Clinical & Logistical Metadata

Test Name	RAB40AL Gene X-Linked Intellectual Disability (XLID) Genetic Test – NGS Full Gene Analysis
Price (AED)	2,800 AED (inclusive of pre-test counselling, analysis, and clinical report)
Turnaround Time	3 to 4 weeks from sample receipt at laboratory
Sample Type / Matrix	Peripheral whole blood (EDTA, 3–5 mL) or dried blood spot (FTA card)
Methodology Used	Next-Generation Sequencing (NGS) with bidirectional Sanger confirmation; CNV detection via read-depth analysis
ICD-10-CM Code	F78, F70, F79
LOINC Code	92880-7
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE